A large study, conducted by Dr. James M. Brophy and his colleagues, from the McGill University Health Center in Montreal, confirms that selective COX2 inhibitors - Vioxx (rofecoxib) and Celebrex (celecoxib) are both associated with increased risk of repeat heart attack. They also found that Vioxx (rofecoxib), but not Celebrex (celecoxib), is associated with increased [...]
Please fill in the following fields
* - Required
Your Name: *
Your E-Mail: *
Your Remarks:
Friend's Name: *
Friend's E-Mail: *
